Figure 1: Inhibition of Proliferation of Murine Bone Marrow-Derived Macrophages (BMDMs) Treated with CSF-1 and CSF-1R Inhibitors (Group 1)




Figure 2: Inhibition of Proliferation of Murine Bone Marrow-Derived Macrophages (BMDMs) Treated with CSF-1 and CSF-1R Inhibitors (Group 2)




Figure 3: Inhibition of Proliferation of Murine Bone Marrow-Derived Macrophages (BMDMs) Treated with CSF-1 and CSF-1R Inhibitors (Group 3)




Figure 4: Phagocytic Activity of Murine Bone Marrow Derived Macrophages




Figure 5: Phagocytic Activity of Primary Murine Microglia Cells




Figure 6: Phagocytic Activity of Primary Murine Microglial Cells following Incubation with DMSO or CSF-1R Inhibitors with LPS




Figure 7: Effect of CSF-1R Inhibitors and Laquinimod on the Proliferation of Unstimulated Primary Murine Microglial Cells




Figure 8: Effect of CSF-1R Inhibitors and Laquinimod on the Proliferation of CSF-1-Stimulated Primary Murine Microglial Cells




Figure 9: Comparison of GENZ-882706-Treated and Vehicle MOG-Induced NOD Progressive EAE Mice




Figure 10: Gene Expression of Anti-Inflammatory and Inflammatory Markers in Spinal Cords from MOG-Induced NOD Progressive EAE Mice




Figure 11: Inflammatory Cytokine Production in the Spinal Cord Following Treatment with Genz-882706




Figure 12: Regulatory Cytokine Production in the Spinal Cord Following Treatment with Genz-882706




Figure 13: Microglia, Monocyte/Macrophage and Lymphocyte Populations in the Brain and Spinal cord after LPS Challenge and Prophylactic Treatment with Genz-882706




Figure 14: Mean Fluorescence Intensities (MFIs) of Activation Markers on Microglia and Monocyte/Macrophage Cell Populations in the Brain after *in vivo* LPS Challenge and Prophylactic Treatment with Genz-882706




Figure 15: Mean Fluorescence Intensities (MFIs) of Activation Markers on Microglia and Monocyte/Macrophage Cell Populations in the Spinal Cord after *in vivo* LPS Challenge and Prophylactic Treatment with Genz-882706




Figure 16: Cell Populations in the Blood after LPS Challenge and Prophylactic Treatment with Genz-882706




Figure 17: Therapeutic treatment with Genz-882706 (100mg/kg or 25mg/kg,top) and Inhibitor A (150mg/kg, bottom).




Figure 18: Histopathology Scoring of Spinal Cord Sections of GENZ-882706-Treated, Vehicle, and Untreated MOG-Induced NOD Progressive EAE Mice




Figure 19: Microglia, Monocyte/Macrophage and Lymphocyte Populations in the Brain after LPS challenge and Prophylactic Treatment with RA10651967




Figure 20: Mean Fluorescence Intensities (MFIs) of Activation Markers on Microglia and Monocyte/Macrophage Populations in the Brain after LPS challenge and Prophylactic Treatment with RA10651967




Figure 21: Cell Populations in the Blood after LPS Challenge and Prophylactic Treatment with RA10651967

